Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report

Introduction

Peripheral T-cell lymphoma (PTCL) represents a small heterogeneous group of non-Hodgkin lymphoma (NHL) that accounts for ~10% of NHLs in western countries and ~25% of NHLs in Japan (1,2). PTCLs generally have a poor outcome with shorter long-term survival compared with B-cell lymphomas. For example, the 5-year overall survival for the World Health Organization (WHO) subtype ‘PTCL-not otherwise specified’ (PTCL-NOS) is 32%. PTCL remains extremely difficult to treat as the majority of subtypes become refractory to even aggressive chemotherapy regimens or relapse, and thus, there is a requirement for novel treatment modalities. Mogamulizumab is a humanized immunoglobulin G1 monoclonal antibody that targets CC chemokine receptor 4 (CCR4). CCR4 is highly expressed by aggressive PTCLs, particularly adult T-cell leukemia/lymphoma (ATL) and cutaneous T-cell lymphomas (CTCLs). A phase II study of mogamulizumab yielded an objective response in 35% of patients and a complete response in 14%, with a median progression-free survival (PFS) of 3 months (3). To date, however, the efficacy of mogamulizumab in patients who become refractory to chemotherapy following autologous stem cell transplantation (ASCT) has not been investigated.

The present study reports a patient with PTCL who became refractory following ASCT and resistant to a salvage therapy, in whom mogamulizumab showed evident efficacy without severe adverse event (AE).

Case report

A 49-year-old woman presented with subcutaneous tumors and erythema from face to trunk with cervical lymphadenopathy. From a biopsy of the tumor, the patient was diagnosed with PTCL-NOS, clinical stage IIIA. The patient received 5 cycles of a regimen containing cyclophosphamide, doxorubicin, vincristine and prednisone, and achieved complete remission (CR). The patient subsequently received an ASCT using the ranimustine/etoposide/cytarabine/melphalan regimen. Following ASCT, the patient remained in CR for 1 month before the skin lesions worsened without lymphadenopathy. The patient received the rituximab, etoposide, methylprednisolone, cytarabine and cisplatin regimen, as a salvage therapy, but the skin lesions remained refractory. The patient received phototherapy, which was similarly ineffective. Re-biopsy of the skin revealed that it was positive for CCR4 (Fig. 1). The patient received mogamulizumab once a week for 8 weeks by intravenous infusion at 1.0 mg/kg. A grade 1 infusion reaction was observed at the first dose; however, no other AE was observed. After 5 weeks, the skin lesions had improved, and after 8 weeks the patient achieved CR (Fig. 2). The patient remained in CR for >1 year.

Figure 1. (A) Hematoxylin and eosin stain of a skin biopsy specimen showing dense infiltration of atypical lymphocytes (original magnification, ×200). (B) Immunohistochemically, these lymphocytes were positive for CC chemokine receptor 4 (original magnification, ×200).

Figure 2. (A) Prior to treatment with mogamulizumab there was a cutaneous nodule on the patient's sole. (B) The cutaneous lesion appeared to improve after 5 cycles of mogamulizumab. (C) The cutaneous lesion almost disappeared after 8 cycles of mogamulizumab.

Discussion

According to the WHO classification, PTCL is a heterogeneous category of mature T-cell neoplasms. The most common mature T-cell neoplasms are PTCL-NOS, angioimmunoblastic T-cell lymphoma anaplastic large-cell lymphoma (ALCL) (4). PTCL remains extremely difficult to treat, as the majority of PTCL subtypes become refractory to even aggressive chemotherapy regimens or relapse, and thus there is a medical requirement for novel treatment modalities.

Mogamulizumab is the first approved glycol-engineered therapeutic antibody and first approved monoclonal antibody to target CCR4 (5–7). CCR4 is principally expressed on regulatory T cells (Tregs) and helper T cells where it functions to induce homing of these leukocytes to sites of inflammation. Tregs have an essential role in providing and maintaining a favorable environment in which tumors can grow. Mogamulizumab depletes CCR4-positive Tregs, potentially evoking antitumor immune responses by autologous effector cells. This ability is highly pertinent as subsets of malignant T cells are believed to function as CD4-positive Tregs, overexpressing CCR4 (8–10). CCR4 is highly expressed by PTCLs, particularly ATL and CTCLs. A previous study of 169 biopsies demonstrated that CCR4 was expressed in the following PTCL subtypes: ALCL anaplastic large cell kinase (ALK)-negative (67%), PTCL-NOS (38%), angioimmunoblastic T-cell lymphoma (35%), ALCL ALK-positive (4.2%), nasal-type natural killer/T-cell lymphoma (3.7%). Within the PTCL-NOS subtype, CCR4-positive patients had a significantly poorer prognosis compared to CCR4-negative patients and multivariate analysis confirmed that CCR4 expression was an independent unfavorable prognostic factor (11).

Mogamulizumab is developed, owned and manufactured by Kyowa Hakko Kirin Co., Ltd. (Tokyo, Japan). The drug was approved in Japan for the treatment of patients with relapsed/refractory ATL in March 2012 and for the treatment of relapsed/refractory CCR4-positive PTCL and CTCL in March 2014. This agent is currently only available in Japan.

In a phase I study conducted in patients with relapsed ATL and PTCL/CTCL, mogamulizumab was well tolerated at doses of ≤1.0 mg/kg. The overall response rate (ORR) in the 16 patients included in this study was 31% (12). Similarly, a recent phase I/II multicenter, dose-escalation study of mogamulizumab in relapsed patients with CTCL that was conducted in the United States reported an ORR of 36.8% (13). A Japanese multicenter phase II study investigating mogamulizumab in patients previously treated with PTCL or CTCL was published in 2014. In the 37 patients who received mogamulizumab, the ORR was 35%, complete response was 14% and median PFS was 3 months (3). Based on the results of this phase II study, mogamulizumab was approved for use of refractory/relapsed PTCL in Japan.

In the Japanese phase II study, AEs were mild and reversible. The most common of these were hematological events (lymphocytopenia, 81%; leukocytopenia, 43%; thrombocytopenia, 8%; neutropenia, 38%), followed by skin and subcutaneous tissue disorders (51%) (3). The patient in the present study had an infusion reaction, which was observed in 24% of patients in the phase II study. Due to the low frequency of this disease and its endemic features, few physicians have used this agent. Studies that became the foundation of its approval were conducted on relatively small cohorts; therefore, there is a requirement for larger multicenter investigations on the use of mogamulizumab to treat PTCL. The present case is of particular interest, as to the best of our knowledge, the use of mogamulizumab has not been described previously in detail in PTCL cases refractory following ASCT. Three patients who were refractory following ASCT were included in the Japanese phase II study; however, full details of these cases were not included (3). The present case became resistant quickly following ASCT and remained refractory to a salvage therapy, but mogamulizumab monotherapy was markedly effective. In our experience, mogamulizumab has promising efficacy with relapsed PTCL patients following ASCT.

Mogamulizumab is likely to provide new and promising treatment options for patients with CCR4-positive T-cell lymphomas; however, the precise approach may require refinement. For example, patients may benefit from the use of mogamulizumab in combination with other agents. Further studies are required to fully understand the physiological effects of this agent and to determine which subtypes of T-cell lymphoma may receive optimum benefit from this agent.

References